Summaries of the Section H (HML) update

Each month we issue a summary of the HML update. The table on this page gives a preview of the upcoming changes.

18 November 2020 - preview of changes for December 2020

Pharmaceutical

Change

Adalimumab inj 20 mg per 0.4 ml and 40 mg per 0.8 ml syringe (Humira) and inj 40 mg per 0.8 ml pen (HumiraPen)

amended restriction criteria

Amino acid formula (without phenylalanine) (e.g. PKU Anamix Infant) powder 13.1 g protein, 50.1 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can

new listing

Amino acid formula (without phenylalanine) (e.g. PKU Anamix Infant) powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can

to be delisted 1 June 2021

Bupropion hydrochloride (Zyban) tab modified-release 150 mg

addition of HSS

Calcium carbonate tab 1.25 g (500 mg elemental)

Brand change

  • Calci-Tab 500 – new listing and addition of HSS (p’code 2212269)
  • Arrow-Calcium to be delisted 1 May 2021

Cyclizine lactate inj 50 mg per ml, 1 ml ampoule

Brand change

  • Hameln – new listing and addition of HSS (p’code 2595877)
  • Nausicalm to be delisted 1 May 2021

Docetaxel (DBL Docetaxel) inj 10 mg per ml, 2 ml vial

to be delisted 1 June 2021

Dornase alfa (Pulmozyme) nebuliser soln 2.5 mg per 2.5 ml ampoule

amended restriction criteria

Emicizumab (Hemlibra) inj 30 mg in 1 ml vial, 60 mg in 0.4 ml vial, 105 mg in 0.7 ml vial and 150 mg in 1 ml vial

new listing

  • Inj 30 mg in 1 ml vial (p’code 2553511)
  • Inj 60 mg in 0.4 ml vial (p’code 2553546)
  • Inj 105 mg in 0.7 ml vial (p’code 2553554)
  • Inj 150 mg in 1 ml vial (p’code 2553538)

Etanercept (Enbrel) inj 25 mg vial, and inj 50 mg autoinjector and syringe

amended restriction criteria

Extensively hydrolysed formula

  • powder 1.6 g protein, 7.5 g carbohydrate and 3.1 g fat per 100 ml, 900 g can (Aptamil AllerPro SYNEO 1)
  • powder 1.6 g protein, 7.8 g carbohydrate and 3.2 g fat per 100 ml, 900 g can (Aptamil AllerPro SYNEO 2)

amended brand name

Goserelin implant 3.6 mg and 10.8 mg, syringe

Brand change

Teva – new listing and addition of HSS

  • Implant 3.6 mg, syringe (p’code 2597519)
  • Implant 10.8 mg, syringe (p’code 2597527)

Zoladex to be delisted 1 May 2021

Imatinib mesilate cap 400 mg 

Brand change

  • Imatinib-Rex – new listing and addition of HSS (p’code 2594323)
  • Imatinib-AFT to be delisted 1 June 2021

Mitomycin C (Teva) inj 20 mg vial

new listing (p’code 2601761)

Paraldehyde soln 97%

new listing

Pegaspargase (Oncaspar LYO) inj 750  iu per ml, 5 ml vial

amended restriction criteria

 

Pegylated interferon alfa-2a (Pegasys) inj 180 mcg prefilled syringe

amended restriction criteria

Pimecrolimus (Elidel) crm 1%, 15 g

new listing (p’code 2098873)

Rifaximin (Xifaxan) tab 550 mg

addition of HSS

Rituximab (Mabthera) inj 10 mg per ml, 10 ml and 50 ml vial

amended restriction criteria

Tobramycin solution for inhalation 60  mg per ml, 5 ml

Brand change

  • Tobramycin BNM – new listing and addition of HSS (p’code 2601648)
  • TOBI to be delisted 1 May 2021

Tocilizumab (Actemra) inj 20 mg per ml, 4 ml, 10 ml and 20 ml vial

amended restriction criteria

Water (InterPharma) inj 5 ml and 20 ml ampoule

to be delisted 1 June 2021